AI Tool Comparison
Comparing as AI Medical Imaging & DiagnosticsPaige vs Viz.ai
Paige
VS
Viz.ai
Verdict by Category
Detailed Comparison
Feature
Paige
Viz.ai
Pricing
EnterprisePaige operates exclusively on enterprise contracts with hospital pathology departments, cancer centers, and biopharma companies. There is no published pricing or self-serve option.
Clinical deployments are priced based on institution size, scanner ecosystem, patient volume, and AI modules deployed (FullFocus, Paige Prostate, Paige Breast, etc.). Biopharma partnerships are structured as research service agreements for biomarker discovery, companion diagnostic development, and drug trial tissue analysis.
Contact Paige through paige.ai to arrange an enterprise discovery call and platform demonstration.
CustomViz.ai operates exclusively on custom enterprise contracts with hospitals, health systems, and imaging networks. There is no published pricing or self-serve access.
Pricing is negotiated based on hospital type, imaging volume, number of conditions covered, and multi-site deployment needs. Viz.ai's Medicare NTAP designation provides hospitals with an additional reimbursement of approximately $1,040 per qualifying patient encounter, partially offsetting platform costs.
Contact Viz.ai through viz.ai to schedule a demo and begin enterprise procurement discussions.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Computational pathology AI from MSK — the first FDA-cleared platform for AI-assisted cancer diagnosis
AI care coordination platform for stroke, PE, and aortic disease — FDA-cleared algorithms alerting care teams in minutes
Paige Pros & Cons
Pros
- First FDA clearance for AI in primary pathology diagnosis — a historic regulatory milestone
- First CE mark for AI pathology in Europe — validated for clinical use across EU
- Founded on MSK's 25M+ pathology slides — the richest cancer pathology training set in the world
- AIRI infrastructure with 10+ petaFLOPS — enterprise-grade AI compute at clinical scale
- FullFocus viewer is scanner-neutral with FDA clearances for Leica, Hamamatsu, and Philips
- The most credentialed AI pathology company in terms of regulatory approvals
- Backed by Goldman Sachs, Breyer Capital, and Healthcare Venture Partners
Cons
- Enterprise and institutional access only — not available to small or independent pathology labs
- No published pricing — all contracts negotiated through enterprise procurement
- Requires digital pathology infrastructure — scanners, storage, and LIS integration
- Pathologist review and sign-off still required for all AI-generated results
- Focused on pathology and oncology — not a general medical imaging platform
Viz.ai Pros & Cons
Pros
- 12 FDA-cleared algorithms — broadest acute-condition AI portfolio in its class
- Medicare NTAP reimbursement pathway — unique among AI imaging platforms
- 44% reduction in DIDO times for stroke patients — peer-reviewed clinical evidence (ISC 2026)
- 1,000+ hospital deployments across U.S. and Europe
- Backed by Google Ventures, Kleiner Perkins, and Tiger Global — $289M raised
- Simultaneous mobile alerts to full care team — no phone-tag delays
- Expands from neurology to cardiology and pulmonology in one unified platform
Cons
- Enterprise-only pricing — no self-serve or small clinic access
- No published pricing — all contracts are custom
- Primarily focused on acute/time-sensitive conditions — not general radiology reads
- Requires integration with existing hospital imaging infrastructure
- Implementation and onboarding take time for large multi-site systems